Agios Pharmaceuticals, Inc.
tebapivat
Sickle Cell Disease
Countdown
177days
Phase 2 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 2 trial results for tebapivat in Sickle Cell Disease are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 13h ago
“Agios expects to report topline results from its Phase 2 trial in the second half of 2026.”